Lintuzumab

DB14877InvestigationalProtein Based Therapies

Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33
Curator reviewed
Code names: HuM195

Resolves to

Compound

UNIIV00Y10W60WCAS166089-32-3

Targets

P20138CD33

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

14Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lintuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account